Compare Stocks

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSN Imunon		$2.22	$1.80 ▼ $15.75	$13.91M	2.27	150,471 shs	711 shs
NBSE NeuBase Therapeutics	$0.43 -0.8%	$0.71	$0.39 ▼ $4.80	$1.61M	0.83	209,781 shs	88,865 shs
NEPT Neptune Wellness Solutions		$0.39	$0.19 ▼ $28.00	$906K	2.19	462,687 shs	2.25 million shs
VYNE VYNE Therapeutics	$2.25 -2.2%	$2.42	$1.67 ▼ $8.73	$31.73M	1.23	120,914 shs	18,999 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSN Imunon	0.00%	0.00%	0.00%	0.00%	0.00%
NBSE NeuBase Therapeutics	+1.07%	+3.49%	-58.80%	-30.76%	-88.21%
NEPT Neptune Wellness Solutions	0.00%	0.00%	0.00%	-59.18%	-99.22%
VYNE VYNE Therapeutics	-4.17%	-23.33%	+10.05%	+29.21%	-48.43%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSN Imunon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.7058 of 5 stars	3.5	3.0	0.0	0.0	2.4	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSN Imunon	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	3.00	Buy	$7.38	227.78% Upside

Current Analyst Ratings

Latest VYNE, NEPT, NBSE, and CLSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/29/2024	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.75

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSN Imunon	$500K	0.00	N/A	N/A	$9.66 per share	0.00
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
NEPT Neptune Wellness Solutions	$52.62M	0.00	N/A	N/A	($91.90) per share	0.00
VYNE VYNE Therapeutics	$420K	75.54	N/A	N/A	$6.36 per share	0.35

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSN Imunon	-$20.77M	N/A	0.00	N/A	N/A	-5,229.80%	-50.18%	-36.94%	N/A
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
NEPT Neptune Wellness Solutions	-$60.46M	-$106.72	N/A	N/A	N/A	-128.13%	N/A	-141.94%	7/15/2024 (Estimated)
VYNE VYNE Therapeutics	-$28.45M	-$7.04	N/A	N/A	N/A	-6,710.38%	-77.46%	-62.93%	5/9/2024 (Estimated)

Latest VYNE, NEPT, NBSE, and CLSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	VYNE VYNE Therapeutics	-$0.50	-$0.20	+$0.30	-$0.20	$0.15 million	$0.08 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSN Imunon	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSN Imunon	0.13	6.52	6.52
NBSE NeuBase Therapeutics	N/A	2.87	2.87
NEPT Neptune Wellness Solutions	N/A	0.23	0.10
VYNE VYNE Therapeutics	N/A	12.73	12.73

Ownership

Institutional Ownership

Company	Institutional Ownership
CLSN Imunon	12.97%
NBSE NeuBase Therapeutics	12.37%
NEPT Neptune Wellness Solutions	14.44%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
CLSN Imunon	4.66%
NBSE NeuBase Therapeutics	13.90%
NEPT Neptune Wellness Solutions	5.10%
VYNE VYNE Therapeutics	1.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSN Imunon	27	7.10 million	6.77 million	Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
NEPT Neptune Wellness Solutions	58	4.53 million	4.30 million	Not Optionable
VYNE VYNE Therapeutics	10	14.10 million	13.85 million	Not Optionable

VYNE, NEPT, NBSE, and CLSN Headlines

Source	Headline
	VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - April 13 at 8:27 AM
	Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 590.3% americanbankingnews.com - April 11 at 2:54 AM
	Acne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032 pharmiweb.com - March 28 at 12:46 PM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference finance.yahoo.com - March 19 at 9:08 AM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference globenewswire.com - March 19 at 8:00 AM
	Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now zacks.com - March 13 at 10:56 AM
	What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock zacks.com - March 8 at 1:01 PM
	Wall Street Breakfast Podcast: NYCB Gets $1B Investment Boost seekingalpha.com - March 7 at 8:21 AM
	VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 3 at 8:59 AM
	Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments markets.businessinsider.com - February 29 at 7:00 PM
	VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update finanznachrichten.de - February 29 at 10:04 AM
	VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update globenewswire.com - February 29 at 8:00 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium finance.yahoo.com - February 27 at 8:06 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium globenewswire.com - February 27 at 8:00 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference finance.yahoo.com - February 21 at 8:16 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 21 at 8:00 AM
	Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock finance.yahoo.com - February 2 at 7:18 AM
	Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results markets.businessinsider.com - January 10 at 4:27 PM
	Prurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Study fmiblog.com - January 4 at 12:32 AM
	VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors finance.yahoo.com - January 3 at 9:29 AM
	Investing in VYNE Therapeutics Inc [VYNE]: What You Must Know knoxdaily.com - January 1 at 10:15 AM
	VYNE Therapeutics says director Lepore buys 13K shares in co msn.com - November 20 at 3:25 PM
	Cormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Inc finance.yahoo.com - November 14 at 5:53 PM
	VYNE Therapeutics files to sell 36.27M shares for holders msn.com - November 13 at 5:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Imunon

NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Neptune Wellness Solutions

NASDAQ:NEPT

Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.

VYNE Therapeutics

NASDAQ:VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial